Maintenance: From Wednesday, May 30, 2018 6:00 p.m. to Thursday, May 31, 2018 morning, maintenance work on the ZORA servers is scheduled. ZORA will not be available during this period. Thank you for your patience.
Pagani, O; Klingbiel, D; Ruhstaller, T; Nolè, F; Eppenberger, S; Oehlschlegel, C; Bernhard, J; Brauchli, P; Hess, D; Mamot, C; Munzone, E; Pestalozzi, B; Rabaglio, M; Aebi, S; Ribi, K; Rochlitz, C; Rothgiesser, K; Thürlimann, B; Moos, R von; Zaman, K; Goldhirsch, A; Swiss Group for Clinical Cancer Research (SAKK) (2017). Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99. Annals of Oncology, 28(2):305-312.
Koeberle, D; Dufour, J-F; Demeter, G; Li, Q; Ribi, K; Samaras, P; Saletti, P; Roth, A D; Horber, D; Buehlmann, M; Wagner, A D; Montemurro, M; Lakatos, G; Feilchenfeldt, J; Peck-Radosavljevic, M; Rauch, D; Tschanz, B; Bodoky, G; Swiss Group for Clinical Cancer Research (SAKK) (2016). Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Annals of Oncology, 27(5):856-861.
Strasser, F; Blum, D; von Moos, R; Cathomas, R; Ribi, K; Aebi, S; Betticher, D; Hayoz, S; Klingbiel, D; Brauchli, P; Haefner, M; Mauri, S; Kaasa, S; Koeberle, D (2016). The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06). Annals of Oncology, 27(2):324-332.
Zappa, F; Droege, C; Betticher, D; von Moos, R; Bubendorf, L; Ochsenbein, A; Gautschi, O; Oppliger Leibundgut, E; Froesch, P; Stahel, R; Hess, T; Rauch, D; Schmid, P; Mayer, M; Crowe, S; Brauchli, P; Ribi, K; Pless, M (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Lung Cancer, 78(3):239-244.
Ruhstaller, T; von Moos, R; Rufibach, K; Ribi, K; Glaus, A; Spaeti, B; Koeberle, D; Mueller, U; Hoefliger, M; Hess, D; Boehme, C; Thuerlimann, B (2009). Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study. Oncology, 76(2):142-148.
Ribi, K; Bernhard, J; Schuller, J C; Weder, W; Bodis, S; Jörger, M; Betticher, D; Schmid, R A; Stupp, R; Ris, H B; Stahel, R A (2008). Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung Cancer, 61(3):398-404.
D'Addario, G; Rauch, D; Stupp, R; Pless, M; Stahel, R; Mach, N; Jost, L; Widmer, L; Tapia, C; Bihl, M; Mayer, M; Ribi, K; Lerch, S; Bubendorf, L; Betticher, D C (2008). Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Annals of Oncology, 19(4):739-745.
Ribi, K; Relly, C; Landolt, M A; Alber, F D; Boltshauser, E; Grotzer, M A (2005). Outcome of medulloblastoma in children: long-term complications and quality of life. Neuropediatrics, 36(6):357-365.